Management of monochorionic twin pregnancy

Objectives: To provide advice on the management of monochorionic twin pregnancies.

Outcomes: Improved fetal and maternal outcomes from a monochorionic twin pregnancy.

Target audience: All health practitioners providing maternity care and patients.

Values: The evidence was reviewed by the Women’s Health Committee (RANZCOG), and applied to local factors relating to Australia and New Zealand.

Background: This statement was first developed by Women’s Health Committee in March 2011 and most recently reviewed in March 2021.

Funding: The development and review of this statement was funded by RANZCOG.
# Table of Contents

1. Plain Language Summary ........................................................................................................ 3
2. Summary of Recommendations .............................................................................................. 3
3. Discussion and recommendations ............................................................................................ 4
   3.1 What are the specific complications of monochorionic twin pregnancies? .................. 4
   3.2 How is the chorionicity determined in multiple pregnancy? ............................................ 4
   3.3 What are the management considerations for monochorionic gestations? .................. 4
   3.4 What are the recommendations in relation to surveillance for Twin-Twin Transfusion Syndrome (TTTS)? ................................................................. 5
   3.5 How should Twin-Twin Transfusion Syndrome be managed? ........................................ 6
   3.6 What are the recommendations for surveillance in a monochorionic twin pregnancy for selective fetal growth restriction? ......................................................... 6
   3.7 What should be considered in the event of death of one of a monochorionic twin pair? 7
   3.8 What is the recommended gestation at birth? ................................................................ 7
   3.9 Complex monochorionic twin pregnancies ..................................................................... 8
4. References ............................................................................................................................... 8
5. Links to other College statements .......................................................................................... 9
6. Patient information .................................................................................................................. 9
   Appendices ............................................................................................................................ 10
   Appendix A Women’s Health Committee Membership .......................................................... 10
   Appendix B Overview of the development and review process for this statement ............ 11
1. Plain Language Summary

Monochorionic twins are monozygotic; that is, they arise from one fertilised ovum and commonly have a shared placenta with vascular anastomoses between the two fetal circulations. Monochorionic twins are usually diamniotic, with each twin in a separate amniotic sac. Rarely, the twins may be in a single sac (monoamniotic) or even conjoined. These configurations depend upon the stage of development at which the inner cell mass divided.

Monochorionic twins are at risk of specific complications, in addition to the increase in common pregnancy complications that occur in singleton pregnancies. They require careful surveillance by a centre with sufficient experience and expertise to recognise the onset of complications and referral for subspecialty care in the event that complications develop.

2. Summary of Recommendations

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommendation 1</strong></td>
<td>Grade</td>
</tr>
<tr>
<td>Chorionicity is a critical consideration in the management of twin pregnancies and should be determined by ultrasound and documented in all twin pregnancies prior to 14 weeks gestation.</td>
<td>Consensus-based recommendation</td>
</tr>
<tr>
<td><strong>Recommendation 2</strong></td>
<td>Grade</td>
</tr>
<tr>
<td>All women with monochorionic pregnancies should receive 2 weekly ultrasound surveillance for TTTS and IUGR from 16 week’s gestation. Ultrasound should be undertaken by a centre with sufficient experience to recognise these complications and refer appropriately if they occur.</td>
<td>Consensus-based recommendation</td>
</tr>
<tr>
<td><strong>Recommendation 3</strong></td>
<td>Grade</td>
</tr>
<tr>
<td>Ultrasound examination in monochorionic twins should include growth, amniotic fluid volume in each sac and bladder visibility. Umbilical artery and middle cerebral artery Doppler wave forms are routine from 20 weeks but may be required at earlier scans if abnormalities are already apparent.</td>
<td>Consensus-based recommendation</td>
</tr>
<tr>
<td><strong>Recommendation 4</strong></td>
<td>Grade</td>
</tr>
<tr>
<td>Laser ablation of vascular connections is the recommended treatment for the majority of pregnancies with TTTS that require intervention, and referral to a laser surgery facility should be arranged - even where this may require interstate or inter country transfer.</td>
<td>Consensus-based recommendation</td>
</tr>
<tr>
<td><strong>Recommendation 5</strong></td>
<td>Grade</td>
</tr>
<tr>
<td>Early referral is recommended to allow optimal treatment before the onset of severe disease and cervical shortening.</td>
<td>Consensus-based recommendation</td>
</tr>
<tr>
<td><strong>Recommendation 6</strong></td>
<td>Grade</td>
</tr>
<tr>
<td>Monochorionic twins, without IUGR or TTTS, appear to have a higher stillbirth rate than other twin pregnancies despite intensive surveillance. This has led to the recommendation that these pregnancies should be delivered by 37 weeks’ gestation.</td>
<td>Evidence Based recommendation Grade B</td>
</tr>
</tbody>
</table>
3. Discussion and recommendations

3.1 What are the specific complications of monochorionic twin pregnancies?
Monochorionic twin pregnancies exhibit the increased complication rates characteristic of (the more common) dichorionic twin pregnancies (such as risk of preterm birth, and increased maternal risks), but are also at higher risk of a number of specific monochorionic complications. These include:

- Twin to twin transfusion syndrome (TTTS) which will occur in approximately 15 per cent of monochorionic diamniotic (MCDA) twin pregnancies
- Selective intrauterine growth restriction (IUGR), commonly due to unequal placental sharing and velamentous cord insertion
- Death of one twin (see below)
- Twin reversed arterial perfusion (TRAP) sequence

All of these conditions contribute to an overall higher perinatal mortality and preterm birth rate for monochorionic, when compared to dichorionic twins.4,5

3.2 How is the chorionicity determined in multiple pregnancy?
Chorionicity is a critical consideration in the management of twin pregnancies and should be determined by ultrasound and documented in all twin pregnancies during the first trimester.1, 6 Chorionicity is more difficult to determine accurately after chorion and amnion fusion (14 weeks gestation), with only gender discordance providing assurance of dizygosity (and therefore dichorionicity) in later pregnancy.

Recommendation 1

<table>
<thead>
<tr>
<th>Recommendation 1</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chorionicity is a critical consideration in the management of twin pregnancies and should be determined by ultrasound and documented in all twin pregnancies prior to 14 weeks gestation1.</td>
<td>Consensus-based recommendation</td>
</tr>
</tbody>
</table>

3.3 What are the management considerations for monochorionic gestations?
Women should be informed about the implications of a monochorionic pregnancy in early gestation, so that the parents can fully discuss options for managing the pregnancy and plan their future pregnancy care. In particular, they need to know the importance of notifying their obstetric care provider of acute increasing abdominal girth or breathlessness, as these may be signs of polyhydramnios due to TTTS.

Screening tests for aneuploidy have a lower detection rate in twin pregnancies than in singletons and in some centres providing cFTS, nuchal translucency alone will be used without the addition of biochemistry. Non-invasive prenatal testing has an established place for aneuploidy screening in twin pregnancies. A recent meta-analysis has confirmed a pooled sensitivity of 99% for trisomy 21 and 85% for trisomy 18 in twins, although the difference in detection between monozygotic and dizygotic twin pregnancies is a little less certain given the number of monozygotic twin pregnancies contributing to this meta-analysis was relatively low7.
3.4 What are the recommendations in relation to surveillance for Twin-Twin Transfusion Syndrome (TTTS)?

Ultrasound signs such as discordant nuchal translucency or discordant crown-rump length (CRL) in the first trimester increase the likelihood of a later diagnosis of Twin-twin transfusion syndrome (TTTS) or IUGR but are not diagnostic, and have insufficient predictive value to be used as screening tests. These complications still occur in the presence of reassuring early scans.

Frequent ultrasound surveillance of monochorionic twins is recommended; early recognition of TTTS will facilitate referral to a tertiary centre for consideration of intervention in a timely manner. Recommended scanning schedules vary; ISUOG recommends 2 weekly scanning from 16 weeks’ gestation. Two-weekly ultrasound surveillance has been shown to reduce the incidence of ‘late stage’ TTTS at diagnosis. Earlier stage diagnosis and earlier intervention is likely to improve outcomes.

For this reason, it is recommended that all women with monochorionic pregnancies should receive 2 weekly ultrasound surveillance for TTTS and IUGR following their first trimester scan (11-14 weeks) to confirm chorionicity, assess nuchal translucency and early anatomy. Ultrasound should be undertaken by a centre with sufficient experience to recognise these complications and refer appropriately if they occur. Outcomes with TTTS are optimised where there is timely diagnosis and referral to a tertiary centre for consideration of surgical therapy.

<table>
<thead>
<tr>
<th>Recommendation 2</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>All women with monochorionic pregnancies should receive 2 weekly ultrasound surveillance for TTTS and IUGR from 16 weeks’ gestation. Ultrasound should be undertaken by a centre with sufficient experience to recognise these complications and refer appropriately if they occur.</td>
<td>Consensus-based recommendation</td>
</tr>
</tbody>
</table>

TTTS may take one of 2 forms:

**TOPS (Twin Oligohydramnios/Polyhydramnios Sequence)**, affects approximately 10 per cent of monochorionic twins, and is most commonly seen in the midtrimester. This is recognised as ‘classical’ TTTS, with oligohydramnios, poor growth and abnormal umbilical artery Dopplers in the donor, and polyhydramnios progressing to cardiac dysfunction and cardiac failure in the recipient.

**TAPS (Twin Anaemia/Polycythaemia Sequence)** affects up to 5 per cent of monochorionic twins, and 10 per cent of twins that have undergone laser therapy for TOPS. TAPS results in very slow transfusion (5-15ml/24 hours) from donor to recipient, so is not characterised by extreme amniotic fluid discordance and cardiac dysfunction, but by significantly discordant middle cerebral artery (MCA) peak systolic velocities, reflecting anaemia and polycythaemia in the donor and recipient, respectively. It is more common in later pregnancy, and is often recognised as ‘neonatal TTTS’ when very discordant haemoglobin levels are recognised at birth. Nevertheless, TAPS can also be associated with significant fetal anaemia and in utero compromise requiring treatment. For this reason, ultrasound examination in MC twins should include growth, amniotic fluid volume in each sac, bladder visibility and (after 20 weeks) umbilical artery and middle cerebral artery Doppler wave forms.¹
3.5 How should Twin-Twin Transfusion Syndrome be managed?

Twin-Twin Transfusion Syndrome should be managed in a tertiary centre. Laser ablation of vascular connections is the recommended treatment for the majority of pregnancies with early onset, severe TTTS. Referral to a centre with facilities for laser surgery should be offered. Early referral is recommended to allow optimal treatment before the onset of severe disease and cervical shortening. Amnioreduction prior to laser surgery may lead to increased membrane separation and make subsequent laser treatment more difficult. Mild TTTS (e.g. Stage 1), or late gestation disease (e.g. >26 weeks) may occasionally be managed expectantly or by amnioreduction, with or without preterm delivery. Some severe cases may be managed by cord ligation of one twin, particularly if there is a fetal anomaly in one twin. Ongoing surveillance post laser for TAPS (see above) is necessary post laser ablation. This applies even where the placenta has been completely dichorionised (using the Solomon technique, which has been reported to reduce, but not eliminate, the risk of post laser TAPS).

Recommendation 3

| Ultrasound examination in monochorionic twins should include growth, amniotic fluid volume in each sac and bladder volume. Umbilical artery and middle cerebral artery Doppler wave forms are routine from 20 weeks, but may be required at earlier scans if abnormalities are already apparent. | Consensus-based recommendation |

Recommendation 4

| Laser ablation of vascular connections is the recommended treatment for the majority of pregnancies with TTTS that require intervention, and referral to a laser surgery facility should be arranged - even where this would mean interstate transfer. | Consensus-based recommendation |

Recommendation 5

| Early referral is recommended to allow optimal treatment before the onset of severe disease and cervical shortening. | Consensus-based recommendation |

3.6 What are the recommendations for surveillance in a monochorionic twin pregnancy for selective fetal growth restriction?

Selective fetal growth discordance occurs in 10-15% of monochorionic twins and is diagnosed when one twin has an estimated fetal weight (EFW) <10th percentile for gestation and the EFW discordance between the twins is >25%. It has been further subclassified according to the pattern of diastolic flow in the smaller twin. This subclassification has important prognostic implications for the pregnancy outcome. Typical gestation at recognition is 20-24 weeks, with Type II (absence or reversal of forward flow in the umbilical artery on Doppler) and Type III
Management of monochorionic twin pregnancy

3.7 What should be considered in the event of death of one of a monochorionic twin pair?

Death of one twin in a monochorionic pair may result in death or neurological disability in the survivor. These events occur around the time of the fetal death, postulated due to agonal hypotension as the blood volume of the survivor is transfused precipitously into the body of the co-twin through shared vascular communications, or possibly due to the release of thromboplastins from the deceased twin into the shared circulation. One of the advantages of laser therapy (or cord ligation) in TTTS is that it provides some neuroprotection for the surviving twin in the event of co-twin demise. Delivery of the survivor at a preterm gestation will not prevent further damage unless there is evidence of cardiotocography (CTG) abnormalities or significant fetal anaemia. Ongoing ultrasound or MRI assessment of the brain in the survivor to diagnose neurological damage secondary to hypovolaemia should be considered. MCA surveillance should be offered for the surviving twin, and intrauterine transfusion offered if the survivor has evidence of severe anaemia.

In the event of first trimester demise of one of monochorionic twins there is the potential for the development of twin reversed arterial perfusion (TRAP) sequence, where the surviving twin continues to perfuse the deceased twin’s body via placental anastomoses. This rare complication is important to recognise as it carries a high risk of compromise of the surviving twin. Such cases should be managed by or in consultation with centres experienced in their management, both conservative and operative. Early referral is important as operative interventions have greater success and lower complications when performed at earlier gestations.

3.8 What is the recommended gestation at birth?

Monochorionic twins, without IUGR or TTTS, appear to have a higher stillbirth rate than other twin pregnancies despite intensive surveillance⁴. This has led to the recommendation that these pregnancies should be delivered by 37 + 0 weeks gestation. The mode of delivery for monochorionic twins should be individualised for each woman. Vaginal delivery is not contraindicated in monochorionic twin pregnancies⁵. As for all twins, vaginal delivery should only be undertaken where appropriate facilities exist for continuous intrapartum fetal surveillance and recourse to emergency caesarean section.
3.9 Complex monochorionic twin pregnancies

Monochorionic twin pregnancies of higher complexity, such as monoamniotic twins, monochorionic twins with discordant anomalies or monochorionic twins within a triplet pregnancy, are even higher risk and early advice should be sought from units experienced in the management of these rare conditions.

4. References


2. Erratum. Ultrasound in Obstetrics & Gynecology. 2018;52(1):140-.


<table>
<thead>
<tr>
<th>Recommendation 6</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monochorionic twins, without IUGR or TTTS, appear to have a higher stillbirth rate than other twin pregnancies despite intensive surveillance. This has led to the recommendation that these pregnancies should be delivered by 37 weeks’ gestation. This has led to the recommendation that these pregnancies should be delivered by 37+0 weeks’ gestation.</td>
<td>Evidence based recommendation</td>
</tr>
</tbody>
</table>


5. Links to other College statements

Consent and provision of information to patients in Australia regarding proposed treatment (C-Gen 02)

Evidence-based medicine, obstetrics and gynaecology (C-Gen 15)

6. Patient information

A range of RANZCOG Patient Information Pamphlets can be ordered via the RANZCOG website.
### Appendix A Women’s Health Committee Membership

<table>
<thead>
<tr>
<th>Name</th>
<th>Position on Committee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor Yee Leung</td>
<td>Chair and Board Member</td>
</tr>
<tr>
<td>Dr Gillian Gibson</td>
<td>Deputy Chair, Gynaecology</td>
</tr>
<tr>
<td>Dr Scott White</td>
<td>Deputy Chair, Obstetrics</td>
</tr>
<tr>
<td>Associate Professor Ian Pettigrew</td>
<td>Member and EAC Representative</td>
</tr>
<tr>
<td>Dr Kristy Milward</td>
<td>Member and Councillor</td>
</tr>
<tr>
<td>Dr Will Milford</td>
<td>Member and Councillor</td>
</tr>
<tr>
<td>Dr Frank O'Keeffe</td>
<td>Member and Councillor</td>
</tr>
<tr>
<td>Professor Sue Walker</td>
<td>Member</td>
</tr>
<tr>
<td>Dr Roy Watson</td>
<td>Member and Councillor</td>
</tr>
<tr>
<td>Dr Susan Fleming</td>
<td>Member and Councillor</td>
</tr>
<tr>
<td>Dr Sue Belgrave</td>
<td>Member and Councillor</td>
</tr>
<tr>
<td>Dr Marilyn Clarke</td>
<td>ATSI Representative</td>
</tr>
<tr>
<td>Associate Professor Kirsten Black</td>
<td>Member</td>
</tr>
<tr>
<td>Dr Thangeswaran Rudra</td>
<td>Member</td>
</tr>
<tr>
<td>Dr Nisha Khot</td>
<td>Member and SIMG Representative</td>
</tr>
<tr>
<td>Dr Judith Gardiner</td>
<td>Diplomate Representative</td>
</tr>
<tr>
<td>Dr Angela Brown</td>
<td>Midwifery Representative, Australia</td>
</tr>
<tr>
<td>Ms Adrienne Priday</td>
<td>Midwifery Representative, New Zealand</td>
</tr>
<tr>
<td>Ms Ann Jorgensen</td>
<td>Community Representative</td>
</tr>
<tr>
<td>Dr Rebecca Mackenzie-Proctor</td>
<td>Trainee Representative</td>
</tr>
<tr>
<td>Dr Leigh Duncan</td>
<td>Maori Representative</td>
</tr>
<tr>
<td>Prof Caroline De Costa</td>
<td>Co-opted member (ANZJOG member)</td>
</tr>
<tr>
<td>Dr Christine Sammartino</td>
<td>Observer</td>
</tr>
</tbody>
</table>
i. Steps in developing and updating this statement

This statement was originally developed in March 2011 and was most recently reviewed in March 2021. The Women’s Health Committee carried out the following steps in reviewing this statement:

- Declarations of interest were sought from all members prior to reviewing this statement.
- Structured clinical questions were developed and agreed upon.
- An updated literature search to answer the clinical questions was undertaken.
- At the February 2021 teleconference, the existing consensus-based recommendations were reviewed and updated (where appropriate) based on the available body of evidence and clinical expertise. Recommendations were graded as set out below in Appendix B part iii). This statement was approved by RANZCOG Board at their March 2021 meeting.

ii. Declaration of interest process and management

Declaring interests is essential in order to prevent any potential conflict between the private interests of members, and their duties as part of the Women’s Health Committee.

A declaration of interest form specific to guidelines and statements was developed by RANZCOG and approved by the RANZCOG Board in September 2012. The Women’s Health Committee members were required to declare their relevant interests in writing on this form prior to participating in the review of this statement.

Members were required to update their information as soon as they become aware of any changes to their interests and there was also a standing agenda item at each meeting where declarations of interest were called for and recorded as part of the meeting minutes.

There were no significant real or perceived conflicts of interest that required management during the process of updating this statement.

iii. Grading of recommendations

Each recommendation in this College statement is given an overall grade as per the table below, based on the National Health and Medical Research Council (NHMRC) Levels of Evidence and Grades of Recommendations for Developers of Guidelines. Where no robust evidence was available but there was sufficient consensus within the Women’s Health Committee, consensus-based recommendations were developed or existing ones updated and are identifiable as such. Consensus-based recommendations were agreed to by the entire committee. Good Practice Notes are highlighted throughout and provide practical guidance to facilitate implementation. These were also developed through consensus of the entire committee.
## Recommendation category | Description
--- | ---
Evidence-based | A Body of evidence can be trusted to guide practice
 | B Body of evidence can be trusted to guide practice in most situations
 | C Body of evidence provides some support for recommendation(s) but care should be taken in its application
 | D The body of evidence is weak and the recommendation must be applied with caution

## Consensus-based
Recommendation based on clinical opinion and expertise as insufficient evidence available

## Good Practice Note
Practical advice and information based on clinical opinion and expertise

### Appendix C Full Disclaimer

**Purpose**
This Guideline has been developed to provide general advice to practitioners about women’s health issues concerning management of monochorionic twin pregnancy and should not be relied on as a substitute for proper assessment with respect to the particular circumstances of each case and the needs of any person. It is the responsibility of each practitioner to have regard to the particular circumstances of each case.

**Quality of information**
The information available in the Management of Monochorionic Twin Pregnancy is intended as a guide and provided for information purposes only. The information is based on the Australian and New Zealand context using the best available evidence and information at the time of preparation. While the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) had endeavoured to ensure that information is accurate and current at the time of preparation, it takes no responsibility for matters arising from changed circumstances or information or material that may have become subsequently available. The use of this information is entirely at your own risk and responsibility.

For the avoidance of doubt, the materials were not developed for use by patients, and patients must seek medical advice in relation to any treatment. The material includes the views or recommendations of third parties and does not necessarily reflect the views of RANZCOG or indicate a commitment to a particular course of action.

**Third-party sites**
Any information linked in this guideline is provided for the user’s convenience and does not constitute an endorsement or a recommendation or indicate a commitment to a particular course of action of this information, material, or content unless specifically stated otherwise.

RANZCOG disclaims, to the maximum extent permitted by law any responsibility and all liability (including without limitation, liability in negligence) to you or any third party for inaccurate, out of context, incomplete or unavailable information contained on the third-party website, or for whether the information contained on those websites is suitable for your needs or the needs of any third party for all expenses, losses, damages and costs incurred.

**Exclusion of liability**
The College disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) to you or any third party for any loss or damage which may result from your or any third party’s use of or reliance of this guideline, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable for all expenses, losses, damages, and costs incurred.

**Exclusion of warranties**
To the maximum extent permitted by law, RANZCOG makes no representation, endorsement or warranty of any kind, expressed or implied in relation to the materials within or referred to throughout this guideline being in any way inaccurate, out of context, incomplete or unavailable for all expenses, losses, damages and costs incurred.